

Connecting via Winsock to STN

CAS, BIOSIS
SEARCH

Welcome to STN International! Enter x:x

LOGINID:SSSPTAU182DAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:15:05 ON 07 NOV 2007

=> FILE CA BIOSIS
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 10:15:32 ON 07 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:15:32 ON 07 NOV 2007

Copyright (c) 2007 The Thomson Corporation

=> E JOHANSSON B/AU

E1	49	JOHANSSON AXEL/AU
E2	3	JOHANSSON AXEL G/AU
E3	1105 -->	JOHANSSON B/AU
E4	6	JOHANSSON B A/AU
E5	1	JOHANSSON B AA/AU
E6	175	JOHANSSON B B/AU
E7	1	JOHANSSON B B T/AU
E8	20	JOHANSSON B C/AU
E9	23	JOHANSSON B E/AU
E10	88	JOHANSSON B G/AU
E11	9	JOHANSSON B I/AU
E12	1	JOHANSSON B J/AU

=> E JOHANSSON B L/AU

E1	1	JOHANSSON B J/AU
E2	2	JOHANSSON B J E/AU
E3	93 -->	JOHANSSON B L/AU
E4	8	JOHANSSON B M/AU
E5	23	JOHANSSON B O/AU
E6	54	JOHANSSON B R/AU
E7	2	JOHANSSON B V/AU
E8	121	JOHANSSON B W/AU
E9	1	JOHANSSON BACK SVEN A/AU
E10	2	JOHANSSON BARBO B/AU
E11	33	JOHANSSON BARBRO/AU
E12	112	JOHANSSON BARBRO B/AU

=> S E3

L1 93 "JOHANSSON B L"/AU

=> E JOHANSSON BO/AU

E1	4	JOHANSSON BJORN P/AU
E2	2	JOHANSSON BJRN/AU
E3	115 -->	JOHANSSON BO/AU
E4	15	JOHANSSON BO C/AU
E5	1	JOHANSSON BO J E/AU
E6	109	JOHANSSON BO LENNART/AU
E7	1	JOHANSSON BO S/AU
E8	2	JOHANSSON BODIL/AU
E9	144	JOHANSSON BOERJE/AU
E10	1	JOHANSSON BOERJE LENNART INGEMAR/AU
E11	45	JOHANSSON BOO/AU
E12	3	JOHANSSON BORG A/AU

=> S E6

L2 109 "JOHANSSON BO LENNART"/AU

```

=> S L1 OR L2
L3      202 L1 OR L2

=> S MULTI(w)MODAL
L4      896 MULTI(W) MODAL

=> S MULTIMODAL
L5      5389 MULTIMODAL

=> S MIXED(w)MODE
L6      3249 MIXED(W) MODE

=> S L4 OR L5 OR L6
L7      9427 L4 OR L5 OR L6

=> S CATION?(w)EXCHANG?
L8      94953 CATION?(W) EXCHANG?

=> S L7(5A) L8
L9      112 L7(5A) L8

=> S IMMUNOGLOBULIN OR ANTIBODY
L10     1327850 IMMUNOGLOBULIN OR ANTIBODY

=> S L9 AND L10
L11      6 L9 AND L10

=> DUPLICATE REMOVE
ENTER L# LIST OR (END):L11
DUPLICATE PREFERENCE IS 'CA, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):N
PROCESSING COMPLETED FOR L11
L12      5 DUPLICATE REMOVE L11 (1 DUPLICATE REMOVED)

=> SAVE TEMP L12
ENTER NAME OR (END):MULTMOD/A
ANSWER SET L12 HAS BEEN SAVED AS 'MULTMOD/A'

=> S L3 AND L9
L13      5 L3 AND L9

=> DUPLICATE REMOVE
ENTER L# LIST OR (END):L13
DUPLICATE PREFERENCE IS 'CA, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):N
PROCESSING COMPLETED FOR L13
L14      4 DUPLICATE REMOVE L13 (1 DUPLICATE REMOVED)

=> SAVE TEMPL L14
TEMPL IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:
  1. Begin with a letter,
  2. Have 1-12 characters,
  3. Contain only letters (A-Z) and numbers (0-9),
  4. End with /Q for a query (search profile,
    structure, or screen set), /A for an answer
    set, or /L for an L-number list.
  5. Not already be in use as a saved name,
  6. Not be END, SAV, SAVE, SAVED
  7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):L14
L14 IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:

```

1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile, structure, or screen set), /A for an answer set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).

ENTER NAME OR (END):AUTH/A

ANSWER SET L14 HAS BEEN SAVED AS 'AUTH/A'

=> S L12 OR L14

L15 6 L12 OR L14

=> D L15 1-6 BIB AB

L15 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 147:229765 CA

TI Evaluation of multi-modal high salt binding ion exchange materials

AU Yang, Ting; Malmquist, Gunnar; Johansson, Bo-Lennart; Maloisel, Jean-Luc; Cramer, Steven

CS Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA

SO Journal of Chromatography, A (2007), 1157(1-2), 171-177

CODEN: JCRAEY; ISSN: 0021-9673

PB Elsevier B.V.

DT Journal

LA English

AB The performance and selectivity of novel cation and anion exchange multi-modal chromatog. materials were evaluated. Desorption profiles of 13 proteins possessing a range of properties (e.g. size, charge and hydrophobicity) were determined on the cation exchange materials. Batch expts. were carried out by loading individual proteins on each resin at low salt, and examining the desorption of the proteins during sequential washes with increasing salt concns. While all of the resins exhibited some binding of proteins at elevated salt concns., this effect was more pronounced on the resins with aromatic ligands as compared to the materials with aliphatic ligands. As expected, materials with higher ionic capacities exhibited higher binding at elevated salts. In addition, some proteins exhibited high binding at elevated salt concns. to all of the resins. The combined effect of charge and other secondary interactions with these multi-modal chromatog. materials enables high salt binding of a range of proteins as well as unique selectivities for the recovery of certain classes of proteins. Since the anion exchange materials all exhibited high binding at elevated salt concns., the work with these materials focused on a study of elution strategies to remove proteins from these aromatic based materials. After evaluating various elution protocols, a combined strategy of pH change and chaotropic salt were shown to minimize electrostatic and hydrophobic interactions and was an effective elution strategy for this class of anion exchange materials using peanut lectin as a model protein.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 143:284709 CA

TI Two chromatographic steps for purification of antibodies from culture medium or fermentation broth

IN Groenberg, Anna; Johansson, Bo-Lennart; Johansson, Hans J.; Maloisel, Jean-Luc; Thevenin, Nicolas

PA Amersham Biosciences AB, Swed.

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082483	A1	20050909	WO 2005-SE293	20050225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005216847	A1	20050909	AU 2005-216847	20050225
	CA 2552639	A1	20050909	CA 2005-2552639	20050225
	EP 1718386	A1	20061108	EP 2005-722175	20050225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1925898	A	20070307	CN 2005-80006276	20050225
	JP 2007525501	T	20070906	JP 2007-500725	20050225
	IN 2006DN03825	A	20070427	IN 2006-DN3825	20060704
	US 2007167613	A1	20070719	US 2006-589717	20060816
	KR 2007001968	A	20070104	KR 2006-717113	20060825
PRAI	SE 2004-501	A	20040227		
	SE 2004-2558	A	20041021		
	WO 2005-SE293	W	20050225		

AB The present invention relates to a process for the purification of antibodies from one or more impurities in a liquid, which process comprises contacting said liquid with a 1st chromatog. resin comprised of a support to which multimodal ligands were immobilized to adsorb the antibodies to the resin, wherein each multimodal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroarom. ring system; adding an eluent to release the antibodies from the resin; and contacting the eluate so obtained with a 2nd chromatog. resin. In one embodiment, the ring-forming atoms of the aromatic or heteroarom. entity are selected from the group consisting of C, S and O, and the cation exchanging group is a weak cation exchanger.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 143:265469 CA

TI Cation-exchanging group- and aromatic or heteroaromatic ring-containing protein A affinity chromatographic resin for antibody purification

IN Johansson, Bo-Lennart; Johansson, Hans J.; Ljungloef, Anders; Maloisel, Jean-Luc; Thevenin, Nicolas

PA Amersham Biosciences AB, Swed.

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082926	A1	20050909	WO 2005-SE292	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

*check for
copying
US*

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005217348	A1	20050909	AU 2005-217348	20050224
CA 2552823	A1	20050909	CA 2005-2552823	20050224
EP 1718668	A1	20061108	EP 2005-722174	20050224

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1926146	A	20070307	CN 2005-80006267	20050224
IN 2006DN03713	A	20070713	IN 2006-DN3713	20060628
US 2007112178	A1	20070517	US 2006-589718	20060816
KR 2007001969	A	20070104	KR 2006-717115	20060825

PRAI SE 2004-501 A 20040227
WO 2005-SE292 W 20050224

AB The present invention relates to a method of separating antibodies from contaminants in a solution, which method comprises contacting the solution with a chromatog. resin comprised of a support to which multi-modal ligands have been immobilized, wherein a multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroarom. ring system. In one embodiment, the ring-forming atoms of the aromatic or heteroarom. entity are selected among C, S or O, and the cation exchanging group is a weak cation exchanger. The present method may be used as a single step procedure or as a polishing step following a capture on a protein A column.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 140:317361 CA

TI Preparation and characterization of prototypes for multi-modal separation aimed for capture of positively charged biomolecules at high-salt conditions

AU Johansson, Bo-Lennart; Belew, Makonnen; Eriksson, Stefan; Glad, Gunnar; Lind, Ola; Maloisel, Jean-Luc; Norrman, Nils

CS Research and Development, Amersham Biosciences, Uppsala, SE 751-84, Swed.

SO Journal of Chromatography, A (2003), 1016(1), 35-49
CODEN: JCRAEY; ISSN: 0021-9673

PB Elsevier Science B.V.

DT Journal

LA English

AB Several prototypes of aromatic (Ar) and non-aromatic (NoAr) cation-exchange ligands suitable for capture of proteins from high conductivity (.apprx.30 mS/cm)

mobile phases were coupled to Sepharose Fast Flow. These new prototypes of multi-modal cation-exchangers were found by screening a diverse library of multi-modal ligands and selecting cation-exchangers resulting in elution of test proteins at high ionic-strength. Candidates were then tested with respect to breakthrough capacity of bovine serum albumin (BSA), human IgG and lysozyme in buffers adjusted to a high conductivity. By applying a salt-step or a pH-step the recoveries were also tested. We have found that aromatic multi-modal cation-exchanger ligands based on carboxylic acids seem to be optimal for the capture of proteins at high-salt conditions. Exptl. evidence on the importance of the relative position of the aromatic group in order to improve the breakthrough capacity at high-salt conditions has been found. It was also found that an amide group on the α -carbon was essential for capture of proteins at high-salt conditions. Compared to a strong cation-exchanger such as SP Sepharose Fast Flow the best new multi-modal weak cation-exchangers have breakthrough capacities of BSA, human IgG and lysozyme that are 10-30 times higher at high-salt conditions. The new multi-modal cation-exchangers can also be used at

instant

cited on 1/4/99

normal cation-exchange conditions and with either a salt-step or a pH-step (to pH-values where the proteins are neg. charged) to accomplish elution of proteins. In addition, the functional performance of the new cation-exchangers was found to be intact after treatment in 1.0 M sodium hydroxide solution for 10 days. For BSA it was also possible to design cation-exchangers based on non-aromatic carboxyl acid ligands with high capacities at high-salt conditions. A common feature of these ligands is that they contain hydrogen acceptor groups close to the carboxylic group. Furthermore, it was also possible to obtain high breakthrough capacities for lysozyme and BSA of a strong cation-exchanger (SP Sepharose Fast Flow) if Ph groups were attached to the beads. Varying the ligand ratio (SP/Phenyl) could be used for optimizing the function of mixed-ligand ion-exchange media.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 138:264909 CA

TI Generation of ion exchanger media

IN Maloisel, Jean-Luc; Thevenin, Nicolas

PA Amersham Biosciences AB, Swed.

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024588	A1	20030327	WO 2002-SE1650	20020912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460355	A1	20030327	CA 2002-2460355	20020912
AU 2002334542	A1	20030401	AU 2002-334542	20020912
EP 1425092	A1	20040609	EP 2002-798880	20020912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1553828	A	20041208	CN 2002-817837	20020912
JP 2005517517	T	20050616	JP 2003-528676	20020912
NZ 531094	A	20061027	NZ 2002-531094	20020912
US 2004238446	A1	20041202	US 2004-489468	20040310
US 7067059	B2	20060627		
PRAI SE 2001-3084	A	20010914		
WO 2002-SE1650	W	20020912		

AB The present invention relates to a method of generating a separation medium comprising mixed mode cation-exchanger ligands coupled to a base matrix, which method comprises to provide a scaffold comprising a functional group and exhibiting a cyclic core structure; derivatize the scaffold with a reagent comprising a reactive group coupled to a residue R by reacting the functional group of the scaffold with said reactive group; open the cyclic structure of the resulting derivative; and react the product with a base matrix comprising a re-active group. The scaffold presents at least two functionalities; one sulfur-comprising group for coupling to the base matrix and one group that can be transformed into an ionic group.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

*cited
on
1449*

L15 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 129:287429 CA

TI Hydrophilic interaction/cation-exchange chromatography for separation of cyclic peptides

AU Manta, C. T.; Kondejewski, L. H.; Hodges, R. S.

CS Department of Biochemistry and the Medical Research Council of Canada Group in Protein Structure and Function, University of Alberta, Edmonton, AB, T6G 2H7, Can.

SO Journal of Chromatography, A (1998), 816(1), 79-88

CODEN: JCRAEY; ISSN: 0021-9673

PB Elsevier Science B.V.

DT Journal

LA English

AB Mixed-mode hydrophilic interaction/cation-exchange chromatog. (HILIC/CEX) is a novel high-performance technique which provides unique selectivities compared to reversed-phase chromatog. (RPLC) for peptide sepns. Sepns. by HILIC/CEX are effected by linear increasing salt gradients in the presence of acetonitrile (up to 90%), which promotes hydrophilic interactions overlaid on ionic interactions with the ion-exchange matrix. In the present study, the utility of HILIC/CEX has been extended to the separation of cyclic peptides in the form of synthetic model analogs of gramicidin S: Series I comprised six 10-residue cyclic peptide analogs which exhibited amphipathic, rigid 3-pleated sheet conformation; Series 2 comprised 14-residue cyclic diastereomeric analogs of gramicidin S, where only the enantiomeric configuration of a single amino acid side-chain is varied from peptide to peptide. Observation of the retention behavior of these two series of cyclic peptides during HILIC/CEX and RPLC confirmed not only the excellent complementarity of these two chromatog. modes but also highlighted the dramatic sepns. achievable by the mixed-mode approach.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
47.03	47.24

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.38	-4.38

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:24:38 ON 07 NOV 2007

10/589,783

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1185	(530/413).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/11/07 10:40
L2	364	(530/415).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/11/07 10:40
L3	737	(530/416).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/11/07 10:44
L4	785	(210/660).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/11/07 10:45
L5	515	(210/691).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/11/07 10:45
L6	283	(210/692).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2007/11/07 10:45
L7	3342	L1 OR L2 OR L3 OR L4 OR L5 OR L6	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:46
L8	5305	MIXED ADJ MOD\$2	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:46
L9	22527	MULTI ADJ MOD\$2	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:47
L10	22468	MULTIMOD\$2	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:50
L11	45871	L8 OR L9 OR L10	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:50

EAST Search History

L12	54815	CATION ADJ EXCHANG\$4	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:50
L13	62	L11 WITH L12	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:51
L14	282020	ANTIBODY OR IMMUNOGLOBUL\$4	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:51
L15	48	L13 AND L14	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:52
L16	4	L7 AND L13	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2007/11/07 10:52